Leica Biosystems launches Aperio GT Elite scanner
April 2026—Leica Biosystems launched in the U.S. the Aperio GT Elite scanner and Aperio iQC software.
Webinars and Sponsored Roundtables — Register Now
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Marketplace
Thermo Fisher introduces LDT for tacrolimus dosing
April 2026—Thermo Fisher Scientific launched the TacroType pharmacogenetic test, a laboratory-developed test designed to help inform clinicians on dosing tacrolimus, an immunosuppressive drug for transplant recipients.
Siemens launches RUO blood-based tau assays
April 2026—Siemens Healthineers has launched the Atellica IM Phosphorylated tau 217 and Atellica IM Brain Derived Tau assays for research use.
Illumina launches TruPath Genome
April 2026—Illumina has launched TruPath Genome, which provides high-quality, comprehensive whole genome insights for genetic disease. It features a hands-on time of about 10 minutes and generates 16 whole genomes per day.
HelioLiver test available to Quest providers
April 2026—Helio Genomics’ blood-based HelioLiver test is now available to physicians and patients through Quest Diagnostics.
IDT unveils NGS portfolio
March 2026—Integrated DNA Technologies is releasing a suite of next-generation sequencing products that aim to tackle bottlenecks in library preparation, targeted enrichment, and whole genome analysis.
ARUP creates innovation central laboratory
March 2026—ARUP Laboratories has launched an innovation central laboratory to facilitate collaboration with pharmaceutical, biotechnology, and other industry partners.
Henry Schein, CytoChip enter distribution agreement
March 2026—Henry Schein entered into an exclusive distribution agreement with CytoChip for CitoCBC, a 510(k)-cleared, CLIA-waived, cartridge-based CBC system. CitoCBC uses blood collected in a venous draw tube to analyze 16 parameters, including the five-part differential. Test results are available in eight minutes.
BD launches urine collection system
March 2026—BD launched the BD Vacutainer Urine Complete Cup Kit, a three-tube collection system that expands testing capabilities from a single urine specimen.
Guardant360 CDx approved for use with encorafenib
March 2026—The Food and Drug Administration has approved Guardant Health’s Guardant360 CDx as a companion diagnostic to identify patients with BRAF V600E-mutant metastatic colorectal cancer who may benefit from treatment with encorafenib (Braftovi, Pfizer) in combination with cetuximab and chemotherapy in accordance with the approved product labeling.